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Abstract
Background: Febrile neutropenia (FNP) causes significant morbidity and mortality in children undergoing treatment
for cancer. The development of clinical decision rules to help stratify risks in paediatric FNP patients and the use of
inflammatory biomarkers to identify high risk patients is an area of recent research. This study aimed to assess if
procalcitonin (PCT) levels could be used to help diagnose or exclude severe infection in children with cancer who
present with febrile neutropenia, both as a single measurement and in addition to previously developed clinical
decision rules.
Methods: This prospective cohort study of a diagnostic test included patients between birth and 18 years old
admitted with febrile neutropenia to the Paediatric Oncology and Haematology Ward in Leeds between 1st October
2012 and 30th September 2013. Each admission with FNP was treated as a separate episode. Blood was taken for a
procalcitonin level at admission with routine investigations. ‘R’ was used for statistical analysis. Likelihood ratios were
calculated and multivariable logistic regression.
Results: Forty-eight episodes from 27 patients were included. PCT >2 ng/dL was strongly associated with
increased risk of severe infection (likelihood ratio of 26 [95% CI 3.5, 190]). The data suggests that the clinical
decision rules are largely ineffective at risk stratification, frequently over-stating the risk of individual episodes.
High procalcitonin levels on admission are correlated with a greatly increased risk of severe infection.
Conclusions: This study does not show a definitive benefit in using PCT in FNP though it supports further
research on its use. The benefit of novel biomarkers has not been proven and before introducing new tests for
patients it is important their benefit above existing features is proven, particularly due to the increasing importance of
health economics.
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Background
Febrile neutropenia (FNP) is the clinical situation of
raised temperature in the face of a low granulocyte
count following anticancer therapy, indicating a risk of
life-threatening infection. It remains a cause of significant
morbidity and mortality [1]. While a traditional approach is
to manage all cases with prolonged courses of in-hospital
intravenous antibiotics, the development of clinical decision
rules to help stratify risks in paediatric FNP patients has
been an area of recent research [2].
The use of inflammatory biomarkers markers to iden-
tify high-risk patients with febrile neutropenia continues
to be explored [3]. Procalcitonin (PCT) may be better
than C-reactive protein (CRP) in helping identify pa-
tients with severe infection as the cause of temperature
in neutropenia [4, 5]. In patients with FNP significantly
higher PCT levels have been shown in bacteraemias,
particularly gram negative infections, compared to viral
illness or fever of unknown origin. It is claimed that PCT
is not significantly raised in inflammatory conditions or
mucositis [6]. However, other studies have shown no
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significant difference in PCT levels in bacterial infec-
tions. Meta-analysis shows significant heterogeneity be-
tween studies and further research is needed to assess
if procalcitonin is clinically useful [3].
The aim of this study was to assess if procalcitonin
levels can be used to help diagnose or exclude severe in-
fection in children with cancer who present with febrile
neutropenia, both as a single measurement and assessing
it’s additional value of PCT above previously developed
clinical decision rules.
Methods
A prospective cohort of children aged between birth and
18 years old who were undergoing anti-cancer treatment
under the care of the paediatric oncology and haematology
department at Leeds Teaching Hospitals, who consented
and were admitted to the paediatric oncology and haema-
tology ward in Leeds with FNP between 1st October 2012
and 30th September 2013 were included. Febrile neu-
tropenia was defined, as per the Leeds guidelines, as two
temperatures of more than 38.0 °C or one temperature
of more than or equal to 38.5 °C and neutrophil count
of less than 0.75 109/L, in the absence of an already-
microbiologically documented infection. The neutrophil
count is reported as the sum of the mature and immature
band forms of neutrophils. All patients were routinely ex-
amined, admitted, and given broad-spectrum antibiotics
as per the unit policy. Patients were excluded if they were
not neutropenic. Each admission with FNP was treated
as a separate episode. Consent was taken for children
Fig. 1 Classification of infection
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to participate from parents or guardians prior to pres-
entation with FNP.
Additional blood for PCT was taken with admission
(day 1) blood tests for FNP. Further samples for PCT
were taken on day 2 and day 3 of admission for some
patients. PCT samples were analysed at the end of the
study period following data collection of clinical features
and diagnosis for each episode of febrile neutropenia.
PCT testing was done using a Siemens Advia Centaur
XP. Using the classification system from the inter-
national PICNICC (Predicting Infectious Complications
of Neutropenic sepsis in Children with Cancer) group
each episode was classified into severe or non-severe in-
fection (Fig. 1) [3].
‘R’ was used for statistical analysis. PCT values were di-
vided into low (<0.5 ng/ml), intermediate (0.5 to 2 ng/ml)
and high (>2 ng/ml) groups and after log-transformation of
the value as a continuous variable [7–9]. Analysis of PCT
in addition to clinical decision rules was undertaken by
multivariable logistic regression. The null hypothesis was
there would be no improvement in diagnostic accuracy
with the addition of PCT to the previously developed clin-
ical decision rules, with conventional significance defined
as p < 0.05.
Ethical approval was given by Leeds (West) Research
Ethics Committee (REC reference: 12/YH0376). Funding
was provided by Candlelighter’s charity, who had no in-
fluence over the study, the analysis or the decision to
publish. STROBE guidelines for cohort studies were ad-
hered to [10].
Results
The cohort consisted of 48 episodes from 27 patients, with
a median age 5 years 2 months (range 1y3m to 18y3m).
Their diagnoses are in Table 1. Table 2 demonstrates the
Table 1 Diagnosis of patients
Diagnosis Number of patients
Solid tumour 14
Lymphoma 4
Leukaemia 9
Table 2 Distribution of episodes per patient and samples per
day of admission
Number of episodes
per patient
Number of patients samples taken from per day
of admission
Day 1 Day 2 Day 3
1 13 16 11
2 9 3
3 3 1
4 2
Table 3 Predictive power of categorical procalcitonin admission
values
Procalcitonin
level
Severe infection
(number)
Non-severe
infection
(number)
PCT LR [95% CI]
High (>2 ng/dL) 6 1 26 [3.56, 190]
Intermediate
(0.5–2 ng/dL)
1 11 0.394 [0.058, 2.67]
Low (<0.5 ng/dL) 2 27 0.321 [0.093, 1.11]
Table 4 Clinical decision rule Odds Ratios (continuous variable
PCT)
Rule Risk OR of severe infection compared
to ‘low’ risk group
[95% CI]
Department Low 1.0
[Reference value]
Intermediate 0.239
[0.0116, 6.9]
High 0.240
[0.0152, 6.4]
logPCT 23.3
[4.0, 265]
Ammann Low 1.0
[Reference value]
High 1.72
[0.176, 38.1]
logPCT 15.5
[2.78, 166]
Rackoff Low 1.0
[Reference value]
Intermediate 0.86
[0.083, 16.9]
High 0.185
[0.00287, 7.1]
logPCT 27.1
[4.2, 398]
SPOG Low 1.0
[Reference value]
High 2.86
[0.45, 23.9]
logPCT 17.1
[3.52, 160]
Alexander Low 1.0
[Reference value]
High 0.49
[0.058, 3.39]
logPCT 22.9
[3.05, 258]
PINDA Low 1.0
[Reference value]
High 1.60
[0.205, 11.2]
logPCT 15.4
[2.58, 160]
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distribution of episodes per patient and samples per day of
admission.
Assessed as a categorical variable, a high PCT value
(>2 ng/dL) was strongly associated with risk of severe in-
fection of 26 [95% CI 3.5, 190], with unclear associations
with intermediate and low levels (See Table 3).
The additional value of procalcitonin levels, to previ-
ously developed clinical decision rules both as categorical
values and as a continuous variable, was assessed. The
rules were: the departmental guidelines for FNP treat-
ment, Ammann rule [11], Rackoff rule [12], SPOG rule
[13], Alexander rule [14] and PINDA rule [15]. The add-
itional values of procalcitonin are shown as continuous
(see Table 4) and categorical (see Table 5) variables.
These data suggest that the clinical decision rules are
largely ineffective at risk stratification, frequently over-
stating the risk of individual episodes. High procalcitonin
levels on admission are correlated with a greatly increased
risk of severe infection.
There is no evidence of correlation between PCT and
Neutrophil count (r = −0.08). Insufficient data were col-
lected to statistically assess the value of repeated mea-
surements of PCT over time. The values are graphically
displayed in Fig. 2, for the 25 episodes where data on
more than one day were collected.
Discussion
This study supports the hypothesis that procalcitonin
values measured on admission help identify those chil-
dren who will develop a severe infection (as defined in
Fig. 1) during their episode of FNP. Uncertainty remains
as to the extent of this predictive ability, and if multiple-
day testing can improve this further. There were no epi-
sodes of confirmed invasive fungal infection in this study
so no direct conclusion about the value of PCT in fungal
infection could be drawn.
There are seven previous studies [3, 7–9, 16–18] that
have looked at PCT in FNP in children with cancer. The
studies include between 29 to 278 patients, with most
Table 5 Clinical decision rules Odds ratios (categorical variable
PCT)
Rule Risk OR
Department Low 1.0
[Reference value]
Intermediate 0.095
[0.00241, 3.39]
High 0.230
[0.0128, 6.2]
PCT Low 1.0
[Reference value]
PCT Intermediate 0.76
[0.0292, 10.1]
PCT High 107
[10.2, 3460]
Ammann Low 1.0
[Reference value]
High 1.431
[0.124, 32.6]
PCT Low 1.0
[Reference value]
PCT Intermediate 1.180
[0.051, 13.8]
PCT High 70
[6.5, 2040]
Rackoff Low 1.0
[Reference value]
Intermediate 0.65
[0.055, 1.52]
High Not estimable
PCT Low 1.0
[Reference value]
PCT Intermediate 1.29
[0.056, 1.53]
PCT High 178000000
[<0.001, infinite]
SPOG Low 1.0
[Reference value]
High 1.438
[0.145, 14.8]
PCT Low 1.0
[Reference value]
PCT Intermediate 1.391
[0.057, 18.3]
PCT High 79
[8.5, 2016]
Alexander Low 1.0
[Reference value]
High 0.299
[0.0135, 2.93]
PCT Low 1.0
[Reference value]
PCT Intermediate 1.229
[0.053, 14.7]
PCT High 139
[11.3, 5805]
Table 5 Clinical decision rules Odds ratios (categorical variable
PCT) (Continued)
PINDA Low 1.0
[Reference value]
High 1.043
[0.046, 10.1]
PCT Low 1.0
[Reference value]
PCT Intermediate 1.216
[0.051, 14.7]
PCT High 79
[6.0, 3410]
Legend: PCT Low <0.5 ng/dL, PCT Intermediate 0.5 to 2 ng/dL,
PCT High >2 ng/dL
Hemming et al. BMC Pediatrics  (2017) 17:2 Page 4 of 6
less than 100 patients, and 39 to 566 episodes. The re-
sults of these studies are presented in different ways.
The PCT cut off values in the studies varied between
0.5 ng/dL and 2 ng/dL. Three studies that presented
sensitivity and specificity all had sensitivities between 93
and 96.5% for FNP and severe infection. The specificity
was between 70.6 and 97% [7–9]. The high sensitivities
may be due to cut off values for procalcitonin being
chosen to maximize the value of PCT following analysis
of the data instead of prior to analysis as in this study.
The data collected was used to test existing clinical de-
cision rules. Only in the PINDA and Amman rules low
risk groups and the departmental guideline intermediate
risk group were the odds of severe infection lower com-
pared to the high risk group. Little validation of clinical
decision rules have been done outside of their original
dataset so information on how they perform in different
patient groups is important.
No other currently published research study has looked
at the use of PCT on admission in addition to clinical and
laboratory features used in clinical decision rules. Single
tests are rarely used to make decisions and it is important
to see if new diagnostic tests are of additional benefit
to features already used before they become part of
routine use.
Multiple day testing has been previously examined in
two studies. Santolaya et al. [17] showed that PCT levels
did not discriminate between severe sepsis and non-severe
infection at admission but did at day two. Stryjewski et al.
[18] also showed no association with PCT levels and sepsis
at admission but did show an association at 24 and 48 h.
Only limited data was available for PCT on day two and
day three of admission in this study. Although the PCT
levels rose higher on day two in three out of four cases of
severe infection compared to those cases with non-severe
infection the significance is uncertain.
Often young adults are not included in studies, which
limits how the results can be applied, but this study in-
cluded a wide age range. The PCT values were not
known until after data was collected which avoided clin-
ician bias in interpreting the clinical features in light of
the PCT result. As the cut off values were defined prior
to collecting the data this avoided overestimation of the
accuracy of PCT, which may have occurred in other stud-
ies who defined cut off values based on their own data.
Conclusions
This study does not provide conclusive evidence as to
the value, or lack of value, of PCT in episodes of FNP
with and without significant adverse outcomes though it
supports further research on its use in association with
clinical decision rules to identify patients at high risk
and low risk of severe infection to help target appropri-
ate management. Further analysis on larger datasets of
the additional benefit of biomarkers to existing clinical
and laboratory features used is an important step. The
benefit of novel biomarkers has not been proven and be-
fore introducing new tests for patients it is important their
benefit above existing features is proven, particularly due
to the increasing importance of rational diagnostic testing
and “choosing wisely” [19].
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